Identification of Genetic Variants of Human Papillomavirus in a Group of Mexican HIV/AIDS Patients and Their Possible Association with Cervical Cancer

The importance of the human papillomavirus (HPV) as an etiological factor in cervical cancer (CC) has been recognized since the 1980s (Muñoz et al. 1994). In developing regions, CC is the second most common type of cancer. In 2018, it caused approximately 311,000 deaths worldwide (WHO 2020). In America, 3.8 million cases were diagnosed in the same year, and about 1.3 million died (www.paho.org). According to GLOBOCAN (https://gco.iarc.fr), 4,121 women died from CC in Mexico in 2018, 1.3% of all CC-related deaths worldwide.

HPV belongs to the family Papillomaviridae, which comprises non-enveloped viruses with a double-stranded DNA genome of approximately 8,000 base pairs (bp). There are 228 different types of papillomaviruses registered in the International HPV Reference Center (www.hpvcenter.se) (Bruni et al. 2019). Papillomaviruses are classified into low-risk (LR) and high-risk (HR) types based on their association with cancer (Egawa and Doorbar 2017). It is thus crucial to identify the viral genotype with which a patient is infected. Since people who are immunosuppressed due to infection with the human immunodeficiency virus (HIV) have a high incidence of neoplasms (Goedert et al. 1998; Frisch et al. 2001), immunosuppressed women infected with some type of oncogenic HPV have a greater probability of developing cervical cancer (Clifford et al. 2005).

Several studies have shown that HIV-infected women co-infected with LR-HPV and HR-HPV have a two- to seven-fold greater risk of developing low- and high-grade neoplastic intraepithelial lesions, and even CC, compared to HIV-negative women (Mbulawa et al. 2009; Yamada et al. 2008; Videla et al. 2009). In 2018, Hispanic women with HIV were reported to have a higher incidence of HPV-associated CC compared to other ethnic groups (Ortiz et al. 2018). The present study aimed to identify the presence of genetic variants of HPV in a group of HIV-positive Mexican women undergoing antiretroviral therapy. The polymorphisms of the most prevalent genotype were identified. In some areas of Mexico, HPV51 predominates over other genotypes (Gallegos-Bolaños et al. 2017; Jácome-Galarza et al. 2017; Campos et al. 2019).

Presence of HIV and immunological status of the patient. Clinical features. The analysis of the patients’ clinical history showed they had been infected with HIV for an average of 4.6 years after AIDS diagnosis and had been under antiretroviral treatment for an average of 3.46 years. Table I describes the age and the last measurement of CD4+ cells.

HPV prevalence. Amplification assays showed that 77.5% (31/40) of the study population were positive for some HPV type, while 22.5% (9/40) were negative. The following types of HR-HPV were found in 37.5% (15/40) of the samples: 16, 33, 51, 52, 56, 58 and 66. The most frequent types were HPV 51 (17.5%, 7/40), 16 and 58 (both 5%, 2/40), 33, 52, 56 and 66 (each with 2.5%, 1/40). The following LR-HPV types were found in 40% of the samples: 6, 11, 54, 70, 81, 84, 86, 90, 97 and 102. The most frequent types were HPV 6 and 81 (both 7.5%, 3/40), followed by 11 and 70 (both 5%, 2/40), 54, 84, 86, 90, 97 and 102 (2.5% each, 1/40) (Table I, Fig. 1 and 2).

Fig. 1.

Fig. 2.

Pap cytology, HPV and CD4+ lymphocytes status. As can be seen in Table I and Fig. 2, nine (22.5%) patients presented some type of high or low grade cervical intraepithelial neoplasia, five were positive for some type of HPV-HR (33, 51, and 52), four were positive for some type of HPV-LR (54 and 81), and in only one patient with HGSIL the associated type of HPV could not be identified. Thus, no relationship was found between the type of HPV, its risk level, and the age of the patients (< 45, 45–55, and > 55 years) (Fig. 2).

As mentioned, HIV-positive patients were classified into two groups based on the number of CD4+ cells, one with > 350 cells/mm³ and the other with < 350 cells/mm³. It was found that 15 patients out of 40 (37.5%) had CD4+ cell counts > 350 cells/mm³, while 25/40 (62.5%) had < 350 cells/mm³ (Table I). According to the CDC classification system (CD4+ ≥ 500; CD4+200 –499; CD4+ < to 200), and the presence of LR and HR-HPV genotypes was evaluated. According to Spearman’s test, there was no relationship between the prevalence of HPV subtypes and the CD4+ cell count (Kamps et al. 1994).

HPV51 Nucleotide sequence analysis. A multiple alignments of the identified HPV sequences was performed (Fig. 3). Several nucleotide substitutions could be observed in the primary sequence of the L1 protein from clinical samples. The analyzed sequences were translated, and the polymorphisms were identified through multiple alignments (Fig. 4).

Fig. 3.

Fig. 4.

Structural analysis of the polymorphisms of HPV51. There are reports of crystallized structures in the L1 region of different HPV types such as 16 and 18, but they had not been reported for HPV51. The L1 monomer of HPV51 was used to check whether the mutations found in patient samples in the present study corresponded to previously reported mutations (Bishop et al. 2007) in HPV16. The results showed that the mutations found in the present work did not correspond to previously reported mutations. Fig. 5 shows the I21L, E26R, I52L, V71G, and F72I mutations.

Fig. 5.

Cervical cancer is the third most common cancer affecting women in Mexico. The human papillomavirus is a factor associated with the development of this type of cancer. Furthermore, it has been reported that HIV-positive women have a higher prevalence of HPV and cervical cancer than HIV-negative women (Palefsky 2009). An HPV prevalence of 77.5% was found in the present study, which is very similar to what has been reported in other studies carried out in Mexico (Peralta-Rodríguez et al. 2012; Salcedo et al. 2014) and other countries (69–97.2%) (Sahasrabuddhe et al. 2007; Singh et al. 2009). The most common types of HPV in HIV-positive women in African countries such as Kenya and Togo have been reported to be: 16 (4.5%), 18 (3.1 to 8.6%), and 58 (3.6%) (Clifford et al. 2006; Menon et al. 2016; Nyasenu et al. 2019). Other authors have found that HPV types 52 (37.2%) (Clifford et al. 2006; Sahasrabuddhe et al. 2007; Menon et al. 2016; 2019; Nyasenu et al. 2019) and 45 (24.6%) (Desruisseau et al. Abel et al.) have a higher prevalence. Moreover, it was found that HIV patients have a high prevalence (46.7–90.3%) of oncogenic HPV types (Sahasrabuddhe et al. 2007; Desruisseau et al. 2009; Menon et al. 2016; Vyankandondera et al. 2019).

Several studies have long determined that the most common HPV types found in Mexico are HPV16, 18, 31 and 33 (Lazcano-Ponce et al. 2001; López Rivera et al. 2012; Aguilar-Lemarroy et al. 2015; Salcedo et al. 2015; Ortega-Cervantes et al. 2016). However, other genotypes have been detected with high frequency in some regions of Mexico. For example, HPV-31 is the most common type in cities such as Guanajuato and San Luis Potosí (López-Revilla et al. 2008), while genotype 58 is the most frequent in Yucatan (Canche et al. 2010). HPV has been found with a prevalence of 77.5% in Mexico, of which 37.5% corresponds to HR-HPV and 40% to LR-HPV types. Interestingly, the presence of uncommon HPV types has been identified in HIV-positive women such as types 54, 56, 70, 84, 86, 90, 97, and 102, both high and low risk (Table I) (Lazcano-Ponce et al. 2001; Montoya-Fuentes et al. 2001; López-Revilla et al. 2008; Salcedo et al. 2015). The present study found a high prevalence of HPV51 (17.5%) with various grades of the lesion (10% with grade I and II lesions; 2.5% in high- and low-grade intraepithelial neoplasia). The prevalence of HPV51 was thus three times higher than that of HPV16 and seven times higher than that of HPV33. It is consistent with the results of recent studies, which have also found a high prevalence of HPV51 in Mexico (Gallegos-Bolaños et al. 2017; Jácome-Galarza et al. 2017; Campos et al. 2019) and other countries such as Turkey (Gultekin et al. 2018), Greece (Argyri et al. 2018), Italy (Lillo et al. 2001), Tanzania (Mayaud et al. 2001), Kenya (Ferré et al. 2019; Omire et al. 2020) and Canada (de Pokomandy et al. 2018).

The present study results do not show an association between HPV types and the grade of the lesion. The variability in viral prevalence between studies may be due to the geographic location of the studied populations since it has been proposed that HPV types are differentially distributed among different populations and geographic locations (Yamada et al. 2008). As indicated above, there are different types of HPV in Mexico, and it is important to define the geographical distribution of these genotypes among the different regions of the country. A study on the phylogenetic classification of Alphapapillomavirus, including alpha-5 (HPV26, 51, 69, 82), determined that each genotype has an independent evolutionary history, that some regions of the capsid (L1) are more stable than others, and that certain variants are geographically related. Thus, it is important to determine specific polymorphisms (SNP’s) and their geographical dispersion (Chen et al. 2018). Different mutations in the structure of the HPV16 L1 pentamer have been reported (Rodrigues et al. 2018) to affect the loops containing the epitopes recognized by neutralizing antibodies. These mutations also affect the conformation and composition of the epitopes and the antigenicity of the viral surface.

Since the crystallized structure of the L1 region of HPV51 has not been reported before, a monomer was generated by homology to check if the mutations found in the patient samples corresponded to mutations reported before (Bishop et al. 2007). Fig. 5 shows the three-dimensional model of these mutations (the I21L, E26R, I52L, V71G, and F72I mutations are highlighted). The mutations do not structurally alter the monomer, nor are they located in the regions recognized by neutralizing antibodies. Thus, they could be used as population markers, given that these mutations have not been reported in the L1 databases for HPV51 in Mexico. Finally, there is clinical evidence that the CD4+ T-cell dependent response is effective in controlling HIV infection or replication, and it has been suggested that a greater number of CD4+ T-cells could help control HPV infection in HIV-positive patients (Montoya Guarín et al. 2006; Hanisch et al. 2013; Chambuso et al. 2020). The results of the present study do not suggest a similar role for the CD4+ cells in controlling high or low-risk HPV infection, the number of CD4+ cells, or the type and frequency of neoplastic cervical lesions, which is consistent with the results of other studies (Sopracordevole et al. 1996; Cardillo et al. 2001). It was possible to identify a high prevalence of HPV-51 with nucleotide variations that could be used to characterize the viral polymorphism present in this specific population group.